A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors

Distinct Effects of Ligand-Induced PDGFR  and PDGFR  Signaling in the Human Rhabdomyosarcoma Tumor Cell and Stroma Cell Compartments

(2013) M. Ehnman et al.   CANCER RESEARCH

Phosphoproteomics Identifies Driver Tyrosine Kinases in Sarcoma Cell Lines and Tumors

(2012) Y. Bai et al.   CANCER RESEARCH

Stromal Platelet-Derived Growth Factor Receptor   (PDGFR ) Provides a Therapeutic Target Independent of Tumor Cell PDGFR  Expression in Lung Cancer Xenografts

(2012) D. E. Gerber et al.   MOLECULAR CANCER THERAPEUTICS

Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas

(2012) A. Alentorn et al.   NEURO-ONCOLOGY

Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience

(2011) A. Wozniak et al.   ANNALS OF ONCOLOGY

High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event

(2011) Thomas Knösel et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

The  -Receptor for Platelet-Derived Growth Factor Confers Bone-Metastatic Potential to Prostate Cancer Cells by Ligand- and Dimerization-Independent Mechanisms

(2010) M. R. Russell et al.   CANCER RESEARCH

Targeting the   Receptor for Platelet-Derived Growth Factor as a Primary or Combination Therapy in a Preclinical Model of Prostate Cancer Skeletal Metastasis

(2010) M. R. Russell et al.   CLINICAL CANCER RESEARCH

Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature

(2010) Yujia Dai   EXPERT OPINION ON THERAPEUTIC PATENTS

Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

(2008) Michael C. Heinrich et al.   JOURNAL OF CLINICAL ONCOLOGY

The α-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells

(2008) M R Russell et al.   ONCOGENE